Results 81 to 90 of about 37,289 (232)
Онкогематология, 2016 Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxicity ...
M. S. Fominykh +5 more
doaj +1 more source
ChemistryEurope, Volume 4, Issue 2, February 2026.The cis‐2,3‐bis(trifluoromethyl)cyclopropyl chemotype is introduced. The steric demand of this motif is intermediate between that of the heptafluoroisopropyl and prefluorotertbutyl groups; yet, it induces significantly less lipophilicity than these due to its facial polarity.
Daniel Gaviña +5 more
wiley +1 more source
A New Electrochemical Sensor for Direct Detection of Purine Antimetabolites and DNA Degradation
Journal of Analytical Methods in Chemistry, 2019 The development of a reliable electrochemical sensor using a hybrid nanocomposite consisting of ionic liquid (1-butyl-3-methylimidazolium hexafluorophosphate) functionalized graphene oxide (GrO-IL) and gold nanoparticles (AuNPs) stabilized by chitosan ...
Liliya K. Shpigun, Elena Yu. Andryukhina
doaj +1 more source
Brazilian Journal of Pharmaceutical Sciences, 2014 A reverse phase HPLC method is described for the determination of 6-mercaptopurine in bulk and tablets. Chromatography was carried on a C18 column using a mixture of acetonitrile and 0.05 mol/L sodium acetate buffer (10:90 v/v) as the mobile phase at a ...
Vanita Somasekhar
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 457-469, February 2026.Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. The pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy remains poorly characterized, despite active inflammatory bowel diseases (IBD) being the greatest risk factor for adverse ...
Zrinka Duvnjak +8 more
wiley +1 more source
Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients [PDF]
, 2016 Purpose: Methotrexate administration is associated with frequent adverse neurological events during treatment for childhood acute lymphoblastic leukemia.
Baird, Susan F. +5 more
core +2 more sources
Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 2, Page 495-502, February 2026.Abstract Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged
Giulia D'Arcangelo +11 more
wiley +1 more source
Inhibition of antibody production by thioinosine. 3. Studies on antibody biosynthesis [PDF]
, 1970 The effect of thioinosine on antibody response of immunized rabbits has been studied. When given simultaneously with the antigen, thioinosine profoundly suppresses the formation of humoral antibody.
Kumashiro, Kazuo, Ogata, Masana
core +1 more source
Isolated gastrointestinal Langerhans cell histiocytosis in a 16‐month‐old child: A case report
JPGN Reports, Volume 7, Issue 1, Page 36-39, February 2026.Abstract Langerhans cell histiocytosis (LCH) is a rare disorder characterized by clonal proliferation of Langerhans cells, most often involving the skin or bone. Isolated gastrointestinal (GI) involvement is extremely uncommon in young children. We report a 16‐month‐old girl with a 1‐month history of chronic vomiting, bloody diarrhea, and failure to ...
Al‐Qasim AL‐Bahlani +3 more
wiley +1 more source
Types of Angiopathy in Experimental Autoimmune Disease in Rats [PDF]
, 2017 The purpose and objectives of this work were to study the nature of the heart, lungs and kidneys angiopathy in rats with a model of systemic autoimmune disease, carrying out comparisons of the results with extravasal morphological manifestations of the ...
Iegudina, Y. (Yelizaveta) +3 more
core +2 more sources